Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006721 · ClinicalTrials.gov registry record · Phase 3
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
A Phase 3 study of Lymphoma, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 571
- Enrollment target
- 20
- Study locations
NCT00006721: Completed Phase 3 study of Lymphoma, sponsored by SWOG Cancer Research Network.
NCT00006721 is a Phase 3 study of Lymphoma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 571 participants, above the 482-participant average among 299 other Lymphoma trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006721, a Phase 3 study of Lymphoma, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 571 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibodies given together with combination chemotherapy to see how well they work in treating patients with newly-diagnosed non-Hodgkin's lymphoma.
Primary Outcome
Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date
Conditions Studied
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- DRUG doxorubicin
- DRUG vincristine
Study Locations (20)
California
- Alta Bates Summit Comprehensive Cancer Center - Berkeley
- Peninsula Medical Center - Burlingame
- Marin Cancer Institute at Marin General Hospital - Greenbrae
- Sutter Health - Western Division Cancer Research Group - Greenbrae
- Desert Regional Medical Center Comprehensive Cancer Center - Palm Springs
- University of California Davis Cancer Center - Sacramento
- California Pacific Medical Center - California Campus - San Francisco
- Stanford Cancer Center - Stanford
- Sutter Solano Medical Center - Vallejo
Florida
- Center for Cancer Care and Research at Watson Clinic, LLP - Lakeland
- Sacred Heart Cancer Center at Sacred Heart Hospital - Pensacola
- West Florida Cancer Institute at West Florida Hospital - Pensacola - Pensacola
Alaska
- Alaska Regional Hospital Cancer Center - Anchorage
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital - Fairbanks
Arkansas
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center - Fort Smith
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Georgia
- Piedmont Hospital - Atlanta
- Northside Hospital Cancer Center - Atlanta
Connecticut
- Helen and Harry Gray Cancer Center at Hartford Hospital - Hartford
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2001-03 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
What the finished NCT00006721 record still lists
NCT00006721 is an interventional study that assigns participants to a tested intervention. The registered 571 participants enrollment target is mid-sized for trials with a published cap, above the 482-participant average among 299 other Lymphoma trials with a reported enrollment target (18% higher).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which prednisone is the first listed.
NCT00006721 names 20 study sites across 7 states, led by California, Florida, Alaska.
Frequently Asked Questions
What is clinical trial NCT00006721 about?
NCT00006721 is a clinical study titled "S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known whi...
What is the current status of trial NCT00006721?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 571 participants. The study started on 2001-03. Estimated completion is 2025-12.
What conditions does trial NCT00006721 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00006721?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), rituximab (BIOLOGICAL), doxorubicin (DRUG), vincristine (DRUG).
Who is sponsoring clinical trial NCT00006721?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006721 being conducted?
This trial has 20 study locations across Alaska, Arkansas, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006721's enrollment target sits among peer trials
571 13th of 299 higher than 287 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04410796 · 571 participants · Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- NCT05131022 · 572 participants · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06615050 · 572 participants · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia